Intensity Therapeutics Inc.

Intensity Therapeutics, Inc. is a phase 2 clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers.In 2021 we met with FDA to review our a phase 3 program and protocol for our lead drug INT230-6 to treat soft tissue sarcoma. Intensity leverages its DfuseRx℠ technology platform to create novel, proprietary drugs that, following direct injection into tumors, rapidly disperse throughout a tumor and diffuse therapeutic agents into the cancer cells causing tumor necrosis.The Company was awarded a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s (NCI) Vaccine Branch in 2014 and has on-going phase 2 clinical partnerships with Merck and Bristol-Myers Squibb. 

Private: S-1 Filed
IR Website:
Headquarters: Westport, CT

Content provided by Intensity Therapeutics Inc on 3/2/22.


The Intensity Therapeutics management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.


Investor Presentation

Management Overview

Risks & Disclosures